157 related articles for article (PubMed ID: 2154420)
21. A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.
Bailey H; Mulcahy RT; Tutsch KD; Rozental JM; Alberti D; Arzoomanian RZ; Tombes MB; Trump DL; Wilding G
Cancer Res; 1991 Feb; 51(4):1099-104. PubMed ID: 1825475
[TBL] [Abstract][Full Text] [Related]
22. Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours.
Bornstein BA; Herman TS; Hansen JL; Buswell L; Zouranjian PS; Fraser SM; Teicher BA; Svensson GK; Coleman CN
Int J Hyperthermia; 1995; 11(4):489-99. PubMed ID: 7594803
[TBL] [Abstract][Full Text] [Related]
23. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
Lee DJ; Phillips TL; Coleman CN; Cosmatos D; Davis LW; Wasserman TH; Marcial VA; Rubin P
Int J Radiat Oncol Biol Phys; 1992; 22(3):569-71. PubMed ID: 1531215
[TBL] [Abstract][Full Text] [Related]
24. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
Riese NE; Buswell L; Noll L; Pajak TF; Stetz J; Lee DJ; Coleman CN
Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):855-8. PubMed ID: 9369134
[TBL] [Abstract][Full Text] [Related]
26. Sensitization by SR-2508 plus Ro 03-8799.
Stone HB; Luu YH; Lam KN
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1097-100. PubMed ID: 2943707
[TBL] [Abstract][Full Text] [Related]
27. Experimental intra-arterial administration of SR-2508 in the rabbit V2 carcinoma model.
Coldwell DM; Huff J; Marcellus H; Coldwell SG
Br J Radiol; 1989 Mar; 62(735):234-6. PubMed ID: 2522804
[TBL] [Abstract][Full Text] [Related]
28. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
[TBL] [Abstract][Full Text] [Related]
29. Misonidazole with dexamethasone rescue: an escalating dose toxicity study.
Tanasichuk H; Urtasun RC; Fulton DS; Raleigh J
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1735-7. PubMed ID: 6480455
[TBL] [Abstract][Full Text] [Related]
30. Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Buswell L; Recht A; Clark J; Ravikumar T; Busse PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):535-40. PubMed ID: 8005812
[TBL] [Abstract][Full Text] [Related]
31. Clinical trials of misonidazole in the United States.
Wasserman TH; Stetz J; Phillips TL
Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
Eifel PJ; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow toxicity of total-body irradiation combined with radiosensitizers.
Shields AF; Applebaum FR; Graham T; Deeg HJ; Allalunis-Turner J; Chapman JD; Storb R
Radiat Res; 1989 Nov; 120(2):364-9. PubMed ID: 2533359
[TBL] [Abstract][Full Text] [Related]
34. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
Urtasun RC; Coleman CN; Wasserman TH; Phillips TL
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1691-6. PubMed ID: 6237083
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
Roberts JT; Bleehen NM; Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
[TBL] [Abstract][Full Text] [Related]
36. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma.
Evans SM; LaCreta F; Helfand S; VanWinkle T; Curran WJ; Brown DQ; Hanks G
Int J Radiat Oncol Biol Phys; 1991 Apr; 20(4):703-8. PubMed ID: 1825993
[TBL] [Abstract][Full Text] [Related]
37. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
[TBL] [Abstract][Full Text] [Related]
38. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.
Sasai K; Nishimoto S; Shimokawa K; Hisanaga Y; Kitakabu Y; Shibamoto Y; Zhou L; Wang J; Takahashi M; Kagiya T
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1249-54. PubMed ID: 1828462
[TBL] [Abstract][Full Text] [Related]
39. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice.
Iwai H; Matsuno E; Sasai K; Shibamoto Y; Abe M
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):591-4. PubMed ID: 8005821
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix.
Thomas GM; Rauth AM; Black BE; Cummings BJ; Sorenti VL; Bush RS
Br J Cancer; 1982 Jun; 45(6):860-8. PubMed ID: 6284190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
